quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:15:45·897d
NEWSRelease
Medicenna Therapeutics Corp. logo

Medicenna To Present 4 Year Follow-Up Phase 2b Bizaxofusp Survival Data In Recurrent Glioblastoma At The Society For Neuro-Oncology 2023 Annual Meeting

MDNA· Medicenna Therapeutics Corp.
Health Care
Original source

Companies

  • MDNA
    Medicenna Therapeutics Corp.
    Health Care

Related

  • SEC800d
    SEC Form 6-K filed by Medicenna Therapeutics Corp.
  • SEC800d
    SEC Form 6-K filed by Medicenna Therapeutics Corp.
  • 13D/G806d
    SEC Form SC 13G/A filed by Medicenna Therapeutics Corp. (Amendment)
  • SEC820d
    SEC Form 6-K filed by Medicenna Therapeutics Corp.
  • SEC832d
    SEC Form 6-K filed by Medicenna Therapeutics Corp.
  • SEC835d
    SEC Form 6-K filed by Medicenna Therapeutics Corp.
  • SEC840d
    SEC Form 6-K filed by Medicenna Therapeutics Corp.
  • SEC853d
    SEC Form 6-K filed by Medicenna Therapeutics Corp.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022